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INTRODUCTION
Primary biliary cholangitis (PBC) was formerly known as primary
biliary cirrhosis. The name change reflects the fact that cirrhosis
occurs only in the late stage and therefore does not correctly iden-
tify patients with early -stage disease. PBC is an autoimmune liver
disease that is characterized by chronic non-suppurative destruc-
tive cholangitis (CNSDC) associated with the selective destruction
of intrahepatic small bile ducts (interlobular bile ducts and septal
bile ducts) by inflammatory cells, mainly lymphocytes and plasma
cells. The appearance of anti -mitochondrial autoantibodies (AMA)
(90-95%) and a high serum level of IgM are characteristics of the
sera of PBC patients (1, 2). Progressive biliary damage eventually
results in bile duct loss and fibrosis. The mechanisms by which
these antibodies produce liver tissue injury currently remain un-
known ; however, exposure to infectious microbes and/or xeno-
biotics has been suggested to initiate an immune reaction stemming
from an individual’s genetic predisposition and the participation
of innate immunity at the primary stage of PBC.
The immunological interaction between biliary epithelial cells
and surrounding inflammatory cells is an important mechanism
underlying biliary damage. Biliary epithelial cells in PBC express
various cytokines and chemokines in order to generate and sustain
the specific surrounding inflammatory conditions. Damaged bili-
ary epithelial cells have an antigen-presenting ability, with the
aberrant expression of human leukocyte antigen (HLA) class II and
other co-stimulatory molecules (3, 4). Various types of migratory
inflammatory cells become effector cells, which attack biliary epi-
thelial cells and also generate additional cytokines and chemoki-
nes to produce an inflammatory status and progressive fibrosis. A
sign of fragility of biliary epithelium caused by cellular senescence
and the disturbance of autophagy accelerates biliary destruction.
The immunopathological characteristics of injured bile ducts and
infiltrating effector cells were reviewed herein.
1. IMMUNOPATHOLOGICAL CHARACTERISTICS OF
DAMAGED BILIARY EPITHELIAL CELLS AND SUR-
ROUNDING INFLAMMATORY CELLS IN PBC
The small -sized bile ducts ( i.e. interlobular bile ducts), but not
the large-sized bile ducts (i.e. septal and intrahepatic large bile
ducts) are the specific targets of PBC (5). CNSDC is one of the
typical features of the small portal tracts in PBC patients (Fig. 1A).
Infiltrating inflammatory cells invade the epithelium and cause
epithelial interruption and ductal luminal irregularities. Biliary epi-
thelial cells become fragmented and finally disappear (ductopenia,
bile duct loss). Lymphocytes, plasma cells, and often eosinophils
infiltrate the areas surrounding damaged bile ducts (Fig. 1B). Epi-
thelioid granulomas of various sizes constructed by aggregated
macrophages frequently appear in the portal area and hepatic
parenchyma (Fig. 1A).
The biliary epithelial cells of PBC aberrantly express various
types of co-stimulatory factors and adhesion molecules as well as
major histocompatibility complex (MHC) class II molecules, and
may express target molecules (3, 4, 6). Biliary epithelial cells them-
selves express various types of cytokines/chemokines, such as
tumor necrosis factor -alpha (TNF-α), interleukin-6 (IL-6), mono-
cyte chemoattractant protein-1 (MCP-1), regulated on activation,
normal T cell expressed and secreted (RANTES), and fractalkine,
and also generate the specific surrounding immunological microenvi-
ronment (7-12). Biliary epithelial cells also possess several cytokine
receptors against IL-4, IL-6, interferon-gamma (IFN-γ), and TNF-
α ; therefore, these cytokines exert autocrine and paracrine ef-
fects (13).
Previous studies described the profiles of inflammatory cells
surrounding bile ducts in PBC (9, 14-17). Cellular profiles may
change depending on the process of biliary inflammation. Different
immune cell profiles are frequently observed at different portal
areas in the same hepatic tissue section. However, T-cell -related
cellular immunity is generally considered to be involved in the
pathogenesis of CNSDC. Previous studies demonstrated that CD8+
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and CD4+ lymphocytes were the predominant cell types among
inflammatory cells within the portal area in PBC (18, 19). CD8+
lymphocytes are mostly cytotoxic T cells and affect targets via the
perforin/granzyme exocytosis pathway (20, 21). CD4+ lympho-
cytes, particularly pathogenic autoreactive T cells, regulate auto-
immunity around bile ducts in PBC. In the early stage, a Th1-
predominant cytokine milieu is characteristic in CNSDC (22) ;
however, as the disease progresses, IL-12/Th1 and IL-23/Th17
cells both appear to varying extents. In the late stage of PBC, the
ratio of cell formation shifts from Th1 cells to Th17 cells (16). A
decreased number of portal - infiltrating regulatory T cells and an
imbalanced ratio with cytotoxic T cells may be associated with
disease progression (15, 23).
While T cells comprise 55% of the cellular infiltrate, macrophages
account for approximately 30% (24) and B cells/plasma cells for
approximately 10% (19, 25) in early stage showing CNSDC. Eosino-
phils may also constitute some proportion of inflammatory cells
(9, 26, 27). Natural killer (NK) cells and NK T cells account for
approximately 5% of the cellular infiltrate and play important roles
in initiating the breakdown of tolerance (28). Interdigitating den-
dritic cells have been detected between biliary epithelial cells, often
near breaks in the basement membrane and in the periductal granu-
lomatous response (4, 29, 30).
Lymph follicles are frequently observed in the portal tracts of
PBC patients in the early and late stages (31) (Fig. 2A). In an immu-
nohistochemical analysis, the lymph follicles of PBC are regarded
as tertiary lymphoid organs (TLOs) (Fig. 2B). The MECA-79 mono-
clonal antibody recognizes a sulfated carbohydrate epitope pre-
sent on human high endothelial venules (HEVs) called peripheral
lymph node addressin (PNAd). Several HEVs expressing MECA-
79 have been observed in the portal lymph follicles of PBC (Fig. 2C,
D). A follicular dendritic cell (FDC) network expressing CD21 was
detected around the HEV (Fig. 2E). B cells regularly accumulate
along the FDC network and are located in the central part of lymph
follicles. A layer of T cells has been observed in the outer part of
the B cell layer (Fig. 2F). Approximately 80% of PBC cases with
inflammatory cell infiltration showed MECA-79-positive HEV for-
mation. We hypothesized that the inflammatory process may in-
itially and primarily induce MECA-79-positive HEV followed by
the formation of TLOs in the portal area. These TLOs often include
injured bile ducts ; however, TLOs formed at a distant location
from injured bile ducts have also been detected. A direct corre-
lation between TLOs and injured bile ducts has not yet been dem-
onstrated. Takahashi et al. reported that, rather than the follicle -
like aggregation of CD20-positive Bcells, the periductal infiltration
of CD38-positive plasma cells was strongly associated with bile
duct injury (32). TLOs may indirectly correlate with bile duct injury
via the maturation of effector cells.
2. MECHANISMS UNDERLYING BILE DUCT INJURY
IN PBC
There are several pathogenetic possibilities for the mechanisms
underlying bile duct injury in PBC. One hypothesis for the selective
destruction of biliary epithelial cells is that the pyruvate dehydroge-
nase complex (PDC)-E2 subunit, which is typically located in the
mitochondrial inner membrane, is aberrantly expressed on the
surface of biliary epithelial cells (3). Not only PDC-E2 itself, but
also its mutant form and tissue-specific variants may cause the same
phenomenon. Lleo et al. reported the existence of intact immunore-
active PDC-E2 within the apoptotic blebs of cholangiocytes during
the process of apoptosis in PBC (33, 34). An autoimmune response
may accelerate the process against these modified intrinsic PDC-
E2 or related molecules.
Another hypothesis is the occurrence of an immune reaction
against extrinsic antigens located in the biliary epithelium. The
microbial mechanism termed “molecular mimicry” is a strong
hypothesis that is being advanced to account for the break in toler-
ance against mitochondrial antigens.
Epidemiological studies have also suggested that infectious agents
trigger or even exacerbate the disease (35). Gram-positive and
Gram-negative bacteria have both been suspected, particularly
Escherichia coli and Novosphingobium aromaticivorans, which are
the most commonly associated agents that have been reported to
date (36-38). Another candidate for the role of an extrinsic antigen
is xenobiotics (chemicals). Many chemicals, including pharma-
ceuticals and household detergents, have the potential to form
metabolites that show molecular mimicry to PDC-E2 (39, 40).
Amano et al. reported that 2-octynoic acid was unique in both its
quantitative structure-activity relationship analysis and reactivity.
Sera from PBC patients exhibited high Ig reactivity against the
Figure 1
A : Typical images of chronic non-suppurative destructive cholangitis (CNSDC) and epithelioid granuloma (*) near a damaged bile duct () in a
patient with primary biliary cholangitis (PBC). Scale bar : 100 μm.
B : Large numbers of eosinophils as well as lymphocytes and plasma cells infiltrated damaged bile ducts () in a patient with PBC. Scale bar : 100 μm.
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2-octynoic acid-PDC-E2 peptide. 2-Octynoic acid has the poten-
tial to modify PDC-E2 in vivo, and, importantly, is widely used in
daily life such as in perfumes, lipsticks, and many common food
flavorings (41). Mice immunized with 2-octynoic acid serve as a
unique PBC animal model showing autoimmune cholangitis, typi-
cal anti -mitochondrial autoantibodies, and elevated numbers of
liver lymphoid cells with an increase in the number of CD8 (+) cells
in the liver (Fig. 3 A, B) (42). However, difficulties are associated
with demonstrating the localization of 2-octynoic acid in the liver
because of its small molecular size. We recently developed a new
technique to highlight the expression of low-molecular -weight
molecules without any labeling of frozen liver sections using nano-
particle -assisted laser desorption/ionization (nano-PALDI) imaging
mass spectrometry (IMS) (43). We examined the localization of
2-octynoic acid in the liver using 2-octynoic acid- induced PBC
model mice. 2-Octynoic acid was mainly located in the portal area
with marked inflammatory cell infiltration (Fig. 3C) (44). Since
2-octynoic acid was also detected in bile juice, we speculated that
it may be deposited in biliary epithelial cells. These findings imply
that aberrantly deposited extrinsic xenobiotics (chemicals) or their
metabolites function as pathogens.
The activation of the innate immune response appears to be
another key event in early PBC that leads to autoimmune injury of
the small intrahepatic bile ducts. Biliary epithelial cells possess an
innate immune system consisting of the Toll - like receptor (TLR)
family, which recognizes pathogen-associated molecular patterns
Figure 2
A : Lymph follicle formation with germinal centers in the portal tract of a patient with PBC. Scale bar : 100 μm.
B : Schema of tertiary lymphoid organs (TLOs) in the portal tract of a patient with PBC. DC : Interdigitating dendritic cells, HEV : high endothelial
venules, FDC : follicular dendritic cells.
C : Immunostaining for MECA-79, which is a marker of high endothelial venules (HEV) (brown color : positive, counterstaining was performed by
hematoxylin).
D : Higher magnification of MECA-79-positive HEVs (brown color : positive, counterstaining was performed by hematoxylin).
E : Immunostaining for CD21, which is a marker of follicular dendritic cells
(brown color : positive, counterstaining was performed by hematoxylin).
F : Double immunostaining for CD3, a marker of T cells, and CD20, a marker of B cells (brown color : CD3, blue color : CD20).
Figure 3
Mice immunized with 2-octynoic repeatedly showed PBC-like biliary damage with marked inflammatory cell infiltration. Serial images of portal tracts
in the liver tissues of 2 -octynoic acid - induced PBC model mice. A : HE staining, B : CD8 immunostaining, C : MS spectra reconstructed as ion images
of 2 -octynoic acid by high-spatial resolution nano-PALDI imaging mass spectrometry.
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(PAMPs). In PBC, deregulated biliary innate immunity, namely,
hyper-responsiveness to PAMPs, is associated with the pathogene-
sis of cholangiopathy. Moreover, the targeted biliary epithelial cells
may play an active role in the perpetuation of autoimmunity by
attracting immune cells via chemokine secretion. Biliary innate
immune responses induce the production of fractalkine and sev-
eral Th1 shift chemokines, causing the migration of inflammatory
cells including NK cells. TLR4 ligand-stimulated NK cells destroy
autologous biliary epithelial cells in the presence of IFN-α, which
is synthesized by TLR3 ligand-stimulated monocytes. These find-
ings provide new insights into the pathogenesis of PBC (45, 46).
The injured bile ducts and bile ductules of PBC indicate cellular
senescence. Senescent biliary epithelial cells may modulate the
microenvironment surrounding bile ducts by expressing senes-
cence-associated secretory phenotypes (SASP) and contribute to
maintaining inflammation and fibrosis around bile duct lesions in
PBC. Deregulated autophagy followed by cellular senescence in
biliary epithelial cells may be closely related to the abnormal ex-
pression of mitochondrial antigens and subsequent autoimmune
pathogenesis in PBC (47, 48). The biliary epithelial cells of PBC are
exposed to excessive oxidative stress because of a decrease in their
anti -oxidative abilities (49). Oxidative stress may accelerate cel-
lular senescence and the disturbance of the autophagy system,
thereby causing complex biliary damage.
3. RELATIONSHIP BETWEEN THE MANIFESTATION
OF AMA AND BILE DUCT INJURY
Various hypotheses have been proposed for the participation of
AMA in bile duct injury. We recently suggested the protective
contribution of AMA against biliary damage (31). The degree of
bile duct damage around the portal areas was significantly milder in
AMA(+) PBC than in AMA(-) PBC in liver biopsy examinations
of Chinese PBC patients (31). Although detailed comparison of
clinical information between AMA(+) and (-) PBC patients did not
clearly figure out in this report, portal areas from AMA(-) patients
had a significant increase of CD5+ T cells infiltrating the ductal
regions and the levels of B cell infiltrates were worse in the early
phase of bile duct damage. In contrast, Lleo et al. suggested that
AMA promotes the inflammatory process by demonstrating the
prominent production of inflammatory cytokines in the presence
of biliary epithelial cell apoptopes, macrophages from patients with
PBC, and AMA. The secretion of cytokines was inhibited by anti -
CD16 and this was not due to differences in apoptope uptake. More-
over, mature monocyte-derived macrophages from PBC patients
cultured with biliary epithelial cell apoptotic bodies in the presence
of AMAmarkedly increased TNF-related apoptosis- inducing ligand
expression (33).
Several studies have been conducted on AMA in animal models
(23). A unique murine PBC model expressing a dominant negative
form of transforming growth factor beta receptor II (dnTGFbetaRII)
under the control of the CD4 promoter developed colitis and auto-
immune cholangitis with elevated serum levels of IL-6. Based on
these findings, IL-6 -deficient mice with a dnTGF-betaRII back-
ground (dnTGFbetaRII IL-6( -/-)) were produced and examined
for the presence of AMA, cytokine levels, histopathology, and he-
patic immunohistochemistry. Serum AMA levels were decreased
in dnTGFbetaRII IL-6( -/-) mice ; however, autoimmune cholangi-
tis was significantly exacerbated, including elevated levels of in-
flammatory cytokines, increased numbers of activated T cells, and
worsening hepatic pathology. These findings suggest the inhibi-
tory effects of AMA on inflammation.
In order to inhibit the secretion of AMA, autoreactive B-cell de-
pletion therapy using several PBC model mice was also performed.
Moritoki et al. examined the therapeutic efficacy of B-cell depletion
using anti -CD20 (50). In mice in which treatment was initiated at
4-6 weeks of age (early treatment group), anti -CD20 therapy re-
sulted in a significantly reduced incidence of liver inflammation
associated with decreased numbers of activated hepatic CD8(+)
T cells. In contrast, in mice treated at 20-22 weeks of age (late
treatment group), anti -CD20 therapy had a negligible effect on the
liver. All treated animals had reduced B cell numbers, the absence
of AMA, and increased levels of inflammatory cytokines such as
TNF-α in sera. AMA may play some roles in the induction state of
pathogenesis, but not in disease progression in this model (50).
However, B-cell depletion using another murine PBC model (ge-
netic B-cell deficient Igmu(-/-) NOD.c3c4 mice) revealed reduced
B cell numbers, the absence of AMA, and decreased non-B cell
numbers in the liver accompanied by fewer activated NK cells.
Since liver inflammation was significantly attenuated, B cells and
AMA may play important roles in pathogenesis in the model (31).
Given the disparate nature of these findings, we consider the role
of B cells and AMA to depend on the disease phase and a number
of other factors.
4. HYPER-IGM PRODUCTION AND IMMUNOPATHOL-
OGY
Elevated levels of IgM and the presence of AMA are character-
istic of the sera of PBC patients. This increase in serum IgM has
been attributed to chronic B-cell activation induced via the TLR-
signaling pathway. Peripheral blood mononuclear cells (PBMCs)
from PBC patients produce significantly higher levels of polyclonal
IgM and secrete more AMA than controls after an exposure to CpG,
which is a natural ligand for TLR9 (51, 52).
The primary site of IgM production in PBC patients is still un-
clear. Takahashi et al. reported that CD38-positive plasma cells
accumulated around the bile duct in PBC patients (32). These
periductal plasma cells produced IgM and IgG, but not IgA ; there-
fore, they may be candidates for the source of serum IgM. We
focused on the spleen of PBC patients because B-cell maturation
and differentiation occur in the splenic white pulp and produce IgM
in response to an innate immunity stimulus with the capsular poly-
saccharide of a pneumococcus. In an immunohistochemical analy-
sis using surgically resected spleen and autopsied spleen, IgM-
producing plasma cells aggregated near the CD21-positive FDC
network in the germinal center of the spleen of PBC patients (53).
The chemokine, CXCL13, which has a chemotactic function for
B cells, localized near IgM in the lymph follicles of PBC spleen. In
addition to portal - infiltrated B cells in the liver, splenic B cells also
produce IgM in PBC patients. The production of IgM in PBC pa-
tients may be systemically regulated rather than being a local event
in the liver.
5. ESTABLISHMENT OF A NEW THERAPEUTIC AP-
PROACH AGAINST B CELLS IN PBC
A new therapeutic approach that targets B cells in PBC patients
has recently been clinically examined. Tsuda et al. reported the
safe and potential efficacy of B-cell depletion with the anti -CD20
monoclonal antibody rituximab in patients with PBC who had an
incomplete response to ursodeoxycholic acid (UDCA) (54). After
the treatment, serum levels of total IgG, IgM, and IgA as well as
those of AMA-IgA and AMA-IgM decreased significantly from
baseline levels by 16 weeks and subsequently returned to baseline
levels by 36 weeks. Transient decreases in memory B cells and T
cells and an increase in CD25(high) CD4+ T cells were observed
after the treatment. These changes were associated with signifi-
cant increases in the mRNA levels of Foxp3 and TGF-β and a
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decrease in TNF-α in CD4+ T cells. Notably, serum alkaline phos-
phatase levels were significantly reduced up to 36 weeks after the
rituximab treatment. Based on these findings, Tsuda et al. concluded
that the depletion of B cells provides a potential mechanism for the
treatment of patients with PBC who have an incomplete response
to UDCA. However, the potential for herpes zoster reactivation and
upper respiratory infection was acknowledged in a few PBC pa-
tients administered rituximab in this trial. This is regarded as an
important issue of infection control in the performance of B-cell
removal therapy. We also encountered a case of PBC that rapidly
progressed to liver cirrhosis after a treatment including rituximab
(55). A 66-year-old Japanese female patient with PBC who pre-
sented with gastric lymphoma had been treated with a regimen
containing rituximab for incidental malignant lymphoma. She
showed biochemical and immunological improvements, and her
liver histology before and after the rituximab treatment confirmed
the amelioration of liver inflammation. However, she developed
liver cirrhosis soon after the rituximab treatment without biochemi-
cal or immunological deterioration. Autoimmune B-cell removal
therapy has potential as a novel treatment for PBC ; however, cau-
tion needs to be exercised and the careful monitoring of patients
is required.
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